Harmony Biosciences (HRMY)
(Delayed Data from NSDQ)
$27.28 USD
+0.52 (1.94%)
Updated Oct 3, 2025 04:00 PM ET
After-Market: $27.18 -0.10 (-0.37%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
HRMY 27.28 +0.52(1.94%)
Will HRMY be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for HRMY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HRMY
HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal
Can Cannabis Stocks Reverse Their Prolonged Downtrend?
HRMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Harmony Biosciences Holdings, Inc. (HRMY) Misses Q2 Earnings and Revenue Estimates
Analysts Estimate Stoke Therapeutics, Inc. (STOK) to Report a Decline in Earnings: What to Look Out for
Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Other News for HRMY
Death Cross appears for HRMY after 1.94% move
Is HRMY ready to make a move? NR7 shows up after dropping 0.59%
New 52 Week Low appears for HRMY after 2.32% move
NR7 appears for HRMY after 0.29% move
Lower Bollinger Band Walk appears for HRMY after 0.47% move